CDC25C and neoplasm: Dovetailing with past work at the mRNA level, our findings demonstrate that CDC25C can indeed be detected in LUAD tumor sections by immunohistochemistry and that high CDC25C expression levels in the tumors are associated with aggressive histological features and with poor clinical outcomes.